Premature termination codons (PTCs) are responsible for 10-15% of all inherited disease. PTC 31 suppression during translation offers a promising approach to treat a variety of genetic disorders, yet 32 small molecules that promote PTC read-through have yielded mixed performance in clinical trials. 33
INTRODUCTION 45
Premature termination codons (PTCs) arise from single nucleotide mutations that convert a 46 canonical triplet nucleotide codon into one of three stop codons, e.g., TAG, TGA, or TAA. PTCs are 47 often more deleterious than missense mutations because they result in the loss of protein 48 expression. Additionally, mRNA abundance is reduced through nonsense-mediated decay (NMD) 49 and in some cases, truncated proteins may have a dominant negative function 1-3 . Therefore, it is 50 not surprising that PTCs are associated with many severe disease phenotypes, including cystic 51 fibrosis 4 , Duchenne muscular dystrophy, spinal muscular atrophy 5 , infantile neuronal ceroid 52 lipofuscinosis 6 , β-thalessemia 7 , cystinosis 8 , X-linked nephrogenic diabetes insipidus 9 , Hurler 53 syndrome 10 , Usher syndrome 11 , and polycystic kidney disease. Additionally, nonsense mutations 54 occur within the tumor suppressor genes p53 and ATM 12 , further implicating their role in disease. 55 mouse, rat, rabbit, and frog; in addition to a miscoding A9C tRNA Trp We next raised the question of whether ACE-tRNAs that show efficacious suppression of premature 164 stop codons may also induce global readthrough of native stop codons. To address this potential "off 165 target" suppression, a transcriptome-wide quantitative profile of actively engaged ribosomes on all 166 cellular transcripts was obtained by generating libraries of ribosome footprints from HEK293 cells 167 expressing exogenous ACE-tRNAs or a control mock plasmid (puc57GG). Streptomycin was 168 removed from the growth media to prevent readthrough artifacts. For comparison, we also generated 169 the ribosome footprint library from cells in the presence or absence of G418 (150 µM, 48 h). Figure  170 4a shows ribosome footprint densities of G418 and five ACE-tRNAs compared against controls 171 (log2-fold change) on 3'UTR regions. Only transcripts with a minimum threshold of 5 RPKM in the coding sequence and 0.5 RPKM in the 3'UTR in two replicate libraries were included for the 173 quantitation comparison (254 transcripts in G418 and 495-748 transcripts in ACE-tRNAs). In this 174 system, G418 had no observable effect on transcriptome-wide 3'UTR ribosome density for any of 175 the three endogenous stop codon groups. ACE-tRNAs examined here had no detectable change of 176 3'UTR ribosome density with the exception of ACE-tRNA Gln-UAA and Arg-UGA which induced 177 approximately a 2-fold increase in 3'UTR ribosome density for the cognate stop codon 178 complimentary to the ACE-tRNA anticodon. Understanding the biological significance of 2-fold 179 readthrough of protein stops will require further study, but this effect is substantially lower compared 180 to the 100-to 1000-fold suppression of PTC for the same ACE-tRNA. 181
182
Multiple in-frame stop codons are frequently found at the end of genes 37-39 and may cause a minor 183 difference in overall 3'UTR ribosome density for ACE-tRNA and G418 treatment. We therefore 184 examined ribosome occupancy at each nucleotide in the 3'UTR within a 60 nt region downstream of 185 the stop codons. Figure 4b demonstrates the ribosome occupancy surrounding native stop codons 186 for each nucleotide within the region from -35 to +65 nt relative to the first nucleotide of stop codon. 187
Reads were normalized per total million-mapped reads, compared against control cells, and reported 188 as a log2-fold change as in panel A. More than 5,200 transcripts were mapped to at least 1 footprint 189 in the region of interest. ACE-tRNA Gln-UAA and Arg-UGA showed not only notable increased 190 ribosome occupancy in the early region but also characteristic 3-nt periodicity, indicating that the 191 ribosomes were not randomly distributed but followed codon-by-codon movement. ACE-tRNAs for 192 UGA-Trp, UGA-Gly and UAG-Glu, or G418, consistently showed no observable change of ribosome 193 occupancy even in the early region of 3'UTR. Taken together, the ribosome profiling data argue that 194 efficiency of native stop codon suppression by ACE-tRNAs is generally low, and markedly less than 195 the level of PTC suppression. 196
197
We next examined the in vivo activity and stability of ACE-tRNA. We delivered the NLuc-UGA PTC 198 reporter cDNA together with a plasmid encoding four copies of the ACE-tRNA Arg UGA or an 'empty 199 vector control' into mouse skeletal muscle (tibialis anterior) using electroporation [40] [41] [42] . We then 200 compared these data to the expression of the WT NLuc. The data showed that the ACE-tRNA Arg 201 UGA is a potent in vivo PTC suppressor, yielding expression profiles equal to or at some time points, 202 greater than, the full-length WT NLuc, Figure 5a . The signal from the NLuc-UGA plasmid and non-203 electroporated muscle was undetectable. Further, ACE-tRNA Arg suppression activity was stable, as 204 evidenced by the similar duration of NLuc activity between rescued and WT protein, Figure 5b . 205 Furthermore, this duration and intensity of luciferase expression argues in favor of a high in vivo 206 tolerability and negligible repercussion of increased readthrough observed with ACE-tRNA Arg . We 207 next wanted to determine if functional ACE-tRNAs can be delivered as RNA. To this end, we 208 transfected ACE-tRNA Trp and ACE-tRNA Gly RNA transcripts into HEK293 cells that stably express 209 the NLuc-UGA reporter. Here the results indicated that both ACE-tRNAs functioned similarly as 210 when expressed as cDNA plasmids, with comparable fold rescue when delivered as small RNA 211 ( Figure 5c ). Next, we sought to rescue two disease causing mutations in cystic fibrosis 212 transmembrane conductance regulator (CFTR). This large membrane protein controls anion 213 transport across epithelia in multiple organs and missense and nonsense mutations within its 214 reading frame cause cystic fibrosis. To this end, were highly efficacious at suppressing two disease-causing UGA PTCs. To better quantify the 236 relative expression of rescued channels, we compared this rescue to WT CFTR cRNA alone (25ng), 237 and assessed suppression of PTCs in CFTR across a range of ACE-tRNA concentrations. The 238 resulting ACE-tRNA dose response 'current-voltage' relationships are shown in Figure 5f . These 239 data were generated by plotting the steady state ionic current at each voltage versus the voltage 240 used to elicit the measured currents and are a direct measure of channel function and abundance. 241
WT-like current levels of expression were achieved by Gly chr19.trna2, and ~50% for Trp 242 chr17.trna39 ACE-tRNAs, consistent with the predetermined suppression activity and cognate amino 243 acid encoding for these tRNA. When rescued CFTR currents were normalized to WT currents at 35mV, it can be observed that ACE-tRNA Gly (black circles) PTC suppression saturates at 100ng 245 while ACE-tRNA Trp (white squares) does not ( Figure 5f ). Through this analysis, we can estimate that 246 ACE-tRNA Trp RNA transcripts (EC 50 ≅ 3.9μM) are less efficacious than ACE-tRNA Gly (EC 50 ≅ 838nM) 247 at suppressing their respective CFTR nonsense mutations. 248 249 250
DISCUSSION 251
PTCs cause a multitude of human diseases and there are no established therapeutic options for 252 their therapeutic management. Herein, we report the high-throughput cloning and identification, 253 characterization and functional analysis of anticodon-edited tRNA which display efficacious PTC 254 reversion in eukaryotic cells and mouse skeletal muscle. Notably, our screen identifies ACE-tRNA, 255 in total, with the potential to repair a vast majority of known human disease-causing PTC, but this 256 therapeutic will require overcoming tissue and delivery specific challenges. However, the 257 engineered tRNA, once delivered, faithfully encode their cognate amino acid, thus abrogating 258 spurious effects on downstream protein stability, folding, and trafficking, and consequently negating 259 the need for tandem therapies involving protein folding or trafficking agents. When transfected as 260 cDNA, ACE-tRNAs rescued multiple full-length proteins via PTC suppression; a NLuc luciferase 261 reporter, a model protein HDH, and two disease nonsense mutations in CFTR. Potent and stable in 262 vivo PTC suppression in mouse skeletal muscle was displayed by an ACE-tRNA Arg cDNA, 263 suggesting a particularly high level of cellular tolerance for ACE-tRNA activity. The identification of 264 an active ACE-tRNA for arginine in muscle is relevant for the treatment of dystrophinopathies 265 caused by nonsense mutations. Following suit with most genetic diseases, greater than 10 percent 266 of dystrophinopathies are caused by nonsense mutations 43 , where CGA->TGA mutations are most 267 prevalent 43 . Efficient suppression was also achieved with ACE-tRNAs delivered as synthetic RNA 268 transcripts, thus enabling the development of nanoparticle formulations. Future studies will be 269 needed to assess ideal tRNA delivery strategies for each tissue and disease type, where efforts will 270 likely benefit from rapidly expanding technologies for nucleic acid delivery. 271
272
Agents which suppress PTCs have the potential to also produce readthrough of native stop codons. 273
The RNA profiling data presented herein suggest this is, generally, not the case in the cells and for 274 the codon-edited tRNA that we have tested. While detectable readthrough was found with Arg-275 tRNA UGA and Gln-tRNA UAA , no significant effect on global translation termination was measured with 276
Glu-tRNA UAG , UGA-Gly-tRNA UGA and Trp-tRNA UGA . This behavior did not obviously segregate with 277 stop codon type, or the intrinsic PTC suppression activity of the tRNA. One potential reason that 278 ACE-tRNA ineffectually promote readthrough at real stop codons may be due to the contextual 279 sequence landscapes near translation terminations 44 . This possibility is supported by the finding 280 that the composition of termination complexes at PTCs differ from those at native stops 45, 46 . 281 However, in cases where lower level readthrough occurs, there are multiple cellular mechanisms in 282 place to limit both normal stop read-through and damaging effects thereof. Multiple in-frame stop 283 codons are frequently found at the end of genes 37-39 and specialized ubiquitin ligases 47 and 284 ribosome associated pathways 48 are known to identify and degrade proteins with erroneous 285 translation termination. Nonetheless, despite the limited impact seen here in mammalian cells, 286 similar ribosomal profiling experiments should be performed in the desired cell or tissue type for 287 ACE-tRNA delivery and expression. 288
289
Previous studies have shown that the surrounding mRNA sequence influences inherent stop codon 290 suppression efficacy of aminoglycosides and Ataluren PTC 49-52 , and ACE-tRNA may be similarly 291 affected. Further, while gene addition strategies to replace a PTC containing gene, via viral or non-292 viral delivery, have achieved short term benefit in some settings, it may be difficult to regulate 293 transgene expression levels. In contrast, the abundance of protein rescue via ACE-tRNA 294 suppression is coupled to native cellular RNA levels, and thus upper levels of expression will be 295 intrinsically regulated. The biological purpose remains unknown for a majority of the variable 296 isoacceptor tRNA sequences in the human genome, and almost half these genes have been 297 speculated to be transcriptionally silent pseudogenes 53 , however the data here suggest many 298 annotated tRNA are viable. Consistent with this possibility, a suppression approach has been used 299 to identify functional isodecoder tRNAs within Ser and Leu isoacceptor families 54 . The data we 300 present here further demonstrate that the majority of tRNA gene sequences support viable activity 301 when removed from the genomic context, further deepening the mystery for the biological need for a 302 plurality of tRNA, and codon usage. Thus, the high-throughput suppression strategy described here 303 will be useful to identify new types of tRNA sequences with unique suppression properties, and such 304 studies have the potential to produce new RNA reagents as well as advance the molecular 305 understanding tRNA expression and suppression. 
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MATERIALS AND METHODS 409 410
Nonsense reporter HTC plasmid 411
The parent plasmid used was pcDNA3.1(+ RT) and plasmid DNA was prepared and diluted to 125ng/ul (IBI scientific, USA). All clones 445
were sequence verified. Using this method, we achieved 100% cloning efficiency. 446 447
HTS of ACE-tRNA library 448
The day before transfection, HEK293 cells (<40 passages) were plated at 1.4 x 10 4 cells/well in 449 96 well cell culture treated plates in Dulbecco's Modified Essential Medium (DMEM)  450 supplemented with 10% FBS, 1% Pen/Step and 2mM L-Glutamine (Thermofisher, USA). The 451
all-in-one nonsense reporter with ACE-tRNA genes were transfected in triplicate/plate using 452
Calfectin (Signagen, USA). 16hrs post-transfection, the media was aspirated and 20ul of PBS 453 was added to each well. 15ul of lytic Nano-Glo® Luciferase Assay Reagent was added to each 454 well (1:50 reagent to buffer; Promega, USA). The plates were incubated for 2min after 455 rotational shaking and read using a SpectraMax i3 plate reader (Molecular Devices, USA; 456 integration time, 200ms; All wavelengths collected in endpoint mode). Luminescence was 457 averaged across three wells for each experiment and all ACE-tRNAs were repeated >3 times in 458 this fashion. Each plate also contained in triplicate wells transfected with the all-in-one 459 nonsense reporter with no ACE-tRNA to server as control for transfection efficiency and 460 baseline PTC readthrough. All values are reported as ratios of ACE-tRNA luminescence over 461 baseline PTC readthrough luminescence ± SEM. One-way ANOVAs were performed with 462
Tukey's post-hoc analysis across all ACE-tRNAs in a given amino acid family, Supplemental  463  Table 2 . 464 465 CFTR, HDH-his-strep and 4xACE-tRNA expression plasmids 466
For expression in mammalian cells, the cDNA for the coding region and 200 base-pair of the 3' 467 untranslated region (UTR) of human CFTR was ligated into pcDNA3.1(+) (Promega, USA) using 468
the KpnI and XbaI restriction enzymes. The G542tga and W1282tga mutations were introduced 469
using QuickChange XL II (Stratagene, USA). For expression in Xenopus laevis oocytes, the 470 cDNA for the coding region and 140 base-pair of the 5' and 244 base-pair 3' UTR of human 471 CFTR was ligated into pGEM-HE (Promega, USA). Bothe the G542tga and W1282tga 472 mutations were introduced using QuickChange XL II. The cDNA encoding the E. coli histidinol 473 dehydrogenase was codon optimized for mus musculus and synthesized (BioBasic Inc, 474
Canada) with a c-terminal 8xHis-Strep-tag for protein purification from mammalian cells 475 (supplemental figure X) . The synthesized cDNA was ligated into pcDNA3.1(+) using EcoRI and 476
XhoI restriction sites. The nonsense mutations tag, taa and tga were introduced using 477
QuickChange XL II. To generate multiplexed ACE-tRNA expression plasmids, we generated a 478 novel parent Golden Gate pUC57(amp) plasmid by inserting a BbsI "multiple cloning site" (5'-479 GAATTCTTCCCGAGACGTTCCAAGTCTTCATGAAGACTACAGGCGTCTCCCAGGAAGCT-3'; 480
directional BbsI recognition sequences are underlined and unique four base-pair overhangs for 481 ligation are bolded) between the EcoRI and HindIII restriction sites. pUC57(amp) was chosen 482
as a parent plasmid because it is relatively small in size and lacks backbone BbsI restriction 483 sites and T7 and T3 promoter sequence. A feature included in the HTS plasmid is T7 and T3 484 promoter sequence flanking the ACE-tRNA cassette, giving universal primer binding sequences 485
with comparable melting temperatures (T m ), ideal for pcr amplification. Using the NEB Golden 486
Gate Assembly Tool (https://goldengate.neb.com/editor) we generated pcr primers that 487
annealed to the T7 and T3 flanking sequence and created unique four base-pair overhangs 488
following cleavage of distal BbsI recognition sequence. The end result was the generation of 489 four ACE-tRNA pcr products using universal pcr primers that could be "daisy-chained" through 490 complementary four base-pair overhangs and ligated into the puc57 Golden Gate plasmid using 491 a one-pot Golden Gate reaction. All clones were sequence verified. 492 493 494
Cell culture, protein expression and Western blot 495
HEK293T cells (ATCC, USA) were grown in standard grown media containing (% in v/v) 10% 496 FBS (HiClone, USA), 1% Pen Strep, 1 % L-Glut in high glucose DMEM (Gibco, USA) at 37ºC, 497 5% CO2. cDNA was transfected at 75% confluency using Calfectin according to standard 498 protocols (SignaGen Laboratories, USA). Following 36hrs the cells were scraped and pelleted 499 at 7,000g for 8 min at 4ºC in PBS supplemented with 0.5 µg/ml pepstatin, 2.5 µg/ml aprotinin, 500 2.5 µg/ml leupeptin, 0.1 mM PMSF, 0.75 mM benzamidine. For CFTR expressing cells, the cell 501 pellet was vigorously dounced in 100mM sucrose, 150 mM NaCl, 1mM DTT, 0.5 µg/ml 502 pepstatin, 2.5 µg/ml aprotinin, 2.5 µg/ml leupeptin, 0.1 mM PMSF, 0.75 mM benzamidine, 50 503 mM Tris-HCL ph 7.4 and centrifuged at 100,000g to separate total membranes from the soluble 504 cytosolic proteins. Pellets were solubilized in a buffer containing 1% triton, 250mM NaCl, 50mM 505 tris-HCl pH 7.4, and 0.5 µg/ml pepstatin, 2.5 µg/ml aprotinin, 2.5 µg/ml leupeptin, 0. a resolution of 60,000 in the off axis Orbitrap segment (MS1). Every 3 seconds of the gradient 558 MS1 scans were acquired during the 120 min gradient described above. The most abundant 559 precursors were selected among 2-8 charge state ions at a 2.0E5 threshold. Ions were 560 dynamically excluded for 30 seconds if they were targeted twice in the prior 30 sec. Selected 561 ions were isolated by a multi-segment quadrupole with a mass window on m/z 2, then 562 sequentially subjected to both CID and HCD activation conditions in the IT and the ioin routing 563 multipole respectively. The AGC target for CID was 4.0E04, 35% collision energy, an activation 564 Q of 0.25 and a 100 milliseconds maximum fill time. Targeted precursors were also fragmented 565 by high energy collision-induced dissociation (HCD) at 40% collision energy, and an activation 566 Q of 0.25. HCD fragment ions were analyzed using the Orbitrap (AGC 1.2E05, maximum 567 injection time 110 ms, and resolution set to 30,000 at 400 Th). Both MS2 channels were 568 recorded as centroid and the MS1 survey scans were recorded in profile mode. 569 570
Proteomic Searches. Initial spectral searches were performed with Proteome Discoverer 571 version 2. 2006; PMID:1703051) plasmids were linearized by 10 x excess of NheI-HF restriction enzyme 581 (site positioned 3' of coding region)(New England BioLabs, USA) for 3hrs at 37°C and purified 582 using standard cDNA precipition methods. All cRNAs were transcribed using the mMessage 583 mMachine T7 Kit (ThermoFisher Scientific, USA). Purification of the cRNA from the transcription 584 reaction was conducted on columns from the RNeasy Mini Kit (Qiagen, Germany). 585
Concentration was determined by absorbance measurements at 260 nm and quality was 586 confirmed on a 1% agarose gel (RNase-free). All cRNA was queued to 1μg/ml before use and 587 all results were generated from ≥2 cRNA preparations. 588 589
In vitro tRNA transcription. Trpchr17.trna39 and Glychr19.trna2, the top performing Trp and 590
Gly ACE-tRNAs, were transcribed in vitro using CellScript T7-Scribe Standard RNA IVT Kit 591 (CELLSCRIPT, USA). Equimolar concentration of T7 oligo (5'-taatacgactcactata-3') was 592 annealed to ACE-tRNA PAGE-purified Ultramers (20ug; Integrated DNA Technologies, 593
Coralville, IA) coding for the ACE-tRNA and preceded by a T7 promoter (italics). Importantly, 594 the three terminal nucleotides containing CCA were included (bold). 
